Although primary hepatocellular carcinoma (PHC) is uncommon in Northern Europe and North America, its world wide incidence is estimated at about 250,000 new cases annually (Waterhouse et al., 1976) . The prognosis of untreated patients with PHC is dismal, the mean survival time from onset of symptoms to death being only a few months (Nagusue et al., 1984) . Even the most effective chemotherapy only increases the median survival time by eleven weeks (Falkson et al., 1984) . PHC is thus one of the most common lethal tumours for which there is an urgent need to find better treatment.
For successful chemotherapy an exploitable biochemical difference must exist between the host cells and tumour cells. Thymidylate synthase is a key target enzyme in cancer chemotherapy (Danenberg, 1977) ; it catalyses the terminal step in the de novo synthesis of deoxythymidylic acid (dTMP) and is therefore a pivotal enzyme in DNA synthesis. It cannot be circumvented by other pathways except by thymidine kinase, a salvage pathway enzyme, which converts pre-formed thymidine into dTMP. Blockade of thymidylate synthase therefore has a drastic effect on tissues that require a high rate of DNA synthesis. Antimetabolites which inhibit thymidylate synthase, either directly (e.g. 5 therapy for many years (Heidelberger et al., 1957; Delmonte & Jukes, 1962) . Problems of toxicity and resistance have however arisen with these drugs. Five fluorouracil may exert toxic effects on normal cells due to its incorporation into RNA and target cells may become resistant to its action by overproducing deoxyuridilic acid (dUMP) or by reducing the appropriate activating enzymes (Chabner, 1982a) . Methotrexate, on the other hand, causes toxicity by inhibition of de novo purine biosynthesis (Hryniuk, 1975; Chabner, 1982b) and target cells may become resistant by virtue of increased production of dihydrofolate reductase and impaired methotrexate transport into the cell (Niethammer & Jackson, 1975) .
A new potent inhibitor of thymidylate synthase is the quinazoline antifolate CB3717 (Figure 1 ) which competes with N5, N10-methylene tetrahydrofolate in the presence of dUMP (Jones et al., 1981; Connick et al., 1983) (Figure 2 ). It has affinity for the catalytic site on the enzyme by virtue of the propargyl substitution at the N1O position. CB3717 requires no metabolic activation so resistance cannot develop by lack of activating enzymes. Also as its primary site of action is thymidylate synthase rather than dihydrofolate reductase (N-(4-(N-((2-amino-4-hydroxyl-6-quinazolinyl) (Gorgun & Watne, 1967) . This paper describes the effect of CB3717 on two PHC cell lines; PLC/PRF/5 (Alexander et al., 1976) and a clonal derivative of Hep 3B (Aden et al., 1979) . This has been studied both in vitro and in xenografts in nude mice (Bassendine et al., 1980 (Bassendine et al., 1980) or 1-2 x 107 Hep 3B cells. Tumours appeared at the site of innoculation 6-12 weeks later in 65% of the mice given PLC/PRF/5 and 96% of the mice given Hep 3B cells. Mice bearing visible growing tumours -5mm in diameter received either 125mg CB3717/kg body wtday-' (low dose) or 200mg CB3717kg-1 body wtday-1 (high dose) i.p. for 5 days (6 mice/group). CB3717 was dissolved in N/10 NaOH and the pH adjusted to 8.5 before i.p. injection. In addition 6 mice bearing PLC/PRF/5 cell-derived xenograft received a second course of 200mg CB3717kg-1 body wtday i.p. for 5 days (double dose) 9 days after the first one. Six control mice received daily i.p. injections of saline adjusted to pH 8.5.
Tumour growth was followed by direct tumour volume measurement (Vernier callipers) every 7 days and serum collected from the mice at these time points was assayed for AFP (Radioimmunoassay. Hoechst UK).
Results
Cell culture CB3717 studies In both PHC cell lines significant reduction in cell number, compared to controls occurred with CB3717 concentrations of .1 MM. concentration at time 0) and relative tumour volume (estimate of tumour volume time t/volume time 0). Double dose CB3717 caused a further significant reduction in tumour growth rate (Figures 4a,b) . Low dose CB3717 treatment also caused a significant reduction in relative serum AFP; relative tumour volume was reduced but this only achieved significance at 14 days after the start of treatment (Figures 4a,b) . During the low dose study a small PLC/PRF/5 xenograft in one mouse (serum AFP at start of treatment 900IUml-1) regressed completely; the tumour was not palpable for 6 weeks and serum AFP became undetectable. However after 7 weeks the tumour was again detected and serum AFP ( Figure 5 ) and tumour volume increased at a comparable rate to that of controls. This animal was not included in the low dose study group.
Hep 3B xenografts were less responsive to CB3717 treatment, but a significant reduction in relative serum AFP was seen with high dose CB3717 (Figure 6a ). The reduction found in relative volume, compared to controls was not significant for high dose or low dose CB3717 (Figure 6b) .
A loss of body weight was observed in all the mice during the week of CB3717 treatment but subsequently some of this weight was regained. Post-mortem examination of the treated mice revealed some fibrous scarring of the kidneys; this was more marked in those mice which received double dose CB3717.
Discussion
This study shows that the growth of two human hepatocellular carcinoma cell-lines can be inhibited in vitro and in vivo by the quinazoline inhibitor of thymidylate synthase, CB3717. The ID50 for both cell lines is similar to that reported for other cell lines (Jones et al., 1981; Diddens et al., 1983) and falls within the range of plasma levels achieved when CB3717 infusions have been administered to patients in early clinical trials (Alison et al., 1985) . The thymidine incorporation experiments show that the blocking of thymidylate synthase by increasing concentrations of CB3717 causes a progressive increase in the incorporation by exogenous thymidine. This presumably reflects the reduction in dTMP pool size and the activation of thymidine kinase which converts the thymidine to dTMP for DNA synthesis (Figure 2 ). Thymidine kinase activity is known to be raised in liver cancer cells (Weber, 1983; Curtin & Snell, 1983 ) so during CB3717 treatment the availability of thymidine may be a rate limiting factor in PHC growth. This is supported by the observation that the growth inhibitory effect of CB3717 on human lymphoblastoid cells in vitro is prevented by 1OMM of thymidine and the fact that the cytotoxicity of the drug to L1210 cells is only expressed when the thymidine concentration of the medium is <0.1 M (Jackman et al., 1984) . The observed reduction in incorporation of radioactivity from deoxyuridine by the PHC cells with increasing concentrations of CB3717 presumably reflects the inhibition of thymidylate synthase and consequent expansion of endogenous dUMP pool. This hypothesis is supported by experiments showing that 16 h CB3717 treatment of lymphoblastoid (W1-L2) cells in vitro with an ID50 concentration of CB3717 causes an increase in cellular dUMP and decrease in dTTP .
We have studied the effect of CB3717 on these two human PHCs in vivo by using an established xenograft model (Bassendine et al., 1980) , in which serum AFP concentrations correlate with tumour mass (Bassendine et al., 1983) . In patients serial serum AFP levels accurately reflect response to chemotherapy (Johnson & Williams, 1980) (Jones et al., 1981) , but it should be emphasised that these workers started CB3717 treatment when the established tumour was about 2 x 106 cells. By contrast we have allowed the PHC xenografts to grow much larger before starting chemotherapy in order to mimic the situation existing in patients with primary liver cell carcinoma, and have still observed a significant growth inhibitory effect. It is interesting to note that when the very small PLC/PRF/5 derived xenograft was treated with low dose CB3717, complete tumour regression was observed.
The greater sensitivity of PLC/PRF/5 xenografts to CB3717 may be due to a more rapid growth rate. The PLC/PRF/5 xenograft doubling time is -4.5 days (Figure 4) , whereas the Hep 3B xenograft doubling time is 6.5 days (Figure 6 ). PLC/PRF/5 xenografts might therefore be expected to have a greater requirement for DNA synthesis and hence de novo TMP synthesis. Alternatively the greater resistance of Hep 3B cells to CB3717 may be due to a greater activity of the salvage pathway in the presence of CB3717. This is supported by the greater increase in thymidine incorporation observed in Hep 3B cells than PLC/PRF/5 cells following CB3717 treatment. In mice there is a high concentration of circulating thymidine (Taylor et al., 1983 ) so a greater ability of Hep 3B cells to activate thymidine kinase could account for the greater resistance of Hep 3B derived xenografts to CB3717. In vitro however the thymidine concentration is much lower, so thymidine kinase activation would not confer such an advantage on Hep 3B cells, rendering the ID50 similar for both PHC cell lines. To test this hypotheses fully thymidine kinase activity, dTTP pool size and thymidine transport in cells needs to be measured. If the salvage pathway is important inhibitors of thymidine transport such as dipyridamole may be of value (Nelson & Drake, 1984) . Another possible reason for the greater sensitivity of PLC/PRF/5 cells to CB3717 is that thymidine may be rapidly broken down in these cells by dihydrothymine dehydrogenase. This rate limiting enzyme of thymidine catabolism has been shown to be present in high levels in some rat hepatoma cells (Jackson & Weber, 1976) .
The fibrous scarring of the kidneys observed in the mice bearing PHC xenografts is similar to other studies in mice which indicate the dose limiting toxicity is due to CB3717 precipitation in the nephron (Newell et al., 1982) . However these preclinical toxicology studies have shown that this can be prevented by alkalinization and clinically it should be possible to avert potential renal toxicity by appropriate scheduling. The inhibition of growth of two human PLC cell lines both in culture and xenograft models by CB3717 suggests that this quinazoline antifolate 
